Emerging drugs for coeliac disease

Expert Opinion on Emerging Drugs

Volumn 19, Issue 4, 2014, Pages 533-544

  Mooney, Peter D ^a   Hadjivassiliou, Marios ^a   Sanders, David S ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Coeliac disease; Gluten vaccine; Glutenase; Protease; Zonulin inhibitor

Indexed keywords

GLUTEN; HLA INHIBITOR; PROTEIN INHIBITOR; PROTEINASE; TRANGLUTAMINASE INHIBITOR; UNCLASSIFIED DRUG; VACCINE; ZONULIN INHIBITOR;

CELIAC DISEASE; DIET SUPPLEMENTATION; DRUG TARGETING; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; INCIDENCE; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; REVIEW; TREATMENT INDICATION; ADULT; ANIMAL; DIET THERAPY; DRUG DESIGN; GLUTEN FREE DIET; HEALTH SERVICE; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ADULT; ANIMALS; CELIAC DISEASE; DIET, GLUTEN-FREE; DRUG DESIGN; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84912092871     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.959490     Document Type: Review

References (108)

1. Davidson LS, Fountain JR. Incidence of the sprue syndrome; with some observations on the natural history. Br Med J 1950;1(4663):1157-61
2. Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 2010;42(8):587-95
3. Ludvigsson JF, Rubio-Tapia A, van Dyke CT, et al. Increasing incidence of celiac disease in a North American population. Am J Gastroenterol 2013;108(5):818-24
4. Johnston SD, Watson RG, McMillan SA, et al. Prevalence of coeliac disease in Northern Ireland. Lancet 1997;350(9088):1370
5. Sanders DS, Patel D, Stephenson TJ, et al. A primary care cross-sectional study of undiagnosed adult coeliac disease. Eur J Gastroenterol Hepatol 2003;15(4):407-13
6. West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003;52(7):960-5
7. Bingley PJ, Williams AJ, Norcross AJ, et al. Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ 2004;328(7435):322-3
8. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013;62(1):43-52
9. McGowan KE, Castiglione DA, Butzner JD. The changing face of childhood celiac disease in North America: impact of serological testing. Pediatrics 2009;124(6):1572-8
10. Mooney PD, Leeds JS, Libzo N, et al. Case-finding for coeliac disease in secondary care: a prospective multicentre UK study. Dig Liver Dis 2014;46(1):32-5
11. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003;163(3):286-92
12. Hin H, Bird G, Fisher P, et al. Coeliac disease in primary care: case finding study. BMJ 1999;318(7177):164-7
13. van der Windt DA, Jellema P, Mulder CJ, et al. Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA 2010;303(17):1738-46
14. Hadjivassiliou M, Sanders DS, Grunewald RA, et al. Gluten sensitivity: from gut to brain. Lancet Neurol 2010;9(3):318-30
15. Kummen M, Schrumpf E, Boberg KM. Liver abnormalities in bowel diseases. Best Pract Res Clin Gastroenterol 2013;27(4):531-42
16. Sainsbury A, Sanders DS, Ford AC. Meta-analysis: coeliac disease and hypertransaminasaemia. Aliment Pharmacol Ther 2011;34(1):33-40
17. Jabri B, Sollid LM. Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 2006;3(9):516-25
18. Greco L, Romino R, Coto I, et al. The first large population based twin study of coeliac disease. Gut 2002;50(5):624-8
19. Nistico L, Fagnani C, Coto I, et al. Concordance, disease progression, and heritability of coeliac disease in Italian twins. Gut 2006;55(6):803-8
20. Sollid LM, Markussen G, Ek J, et al. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 1989;169(1):345-50
21. Hadithi M, von Blomberg BM, Crusius JB, et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med 2007;147(5):294-302
22. Spurkland A, Sollid LM, Polanco I, et al. HLA-DR and-DQ genotypes of celiac disease patients serologically typed to be non-DR3 or non-DR5/7. Hum Immunol 1992;35(3):188-92
23. Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011;43(12):1193-201
24. Garner CP, Murray JA, Ding YC, et al. Replication of celiac disease UK genome-wide association study results in a US population. Hum Mol Genet 2009;18(21):4219-25
25. Stene LC, Honeyman MC, Hoffenberg EJ, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006;101(10):2333-40
26. Mooney PD, Evans KE, Barrett SM, et al. Re: "Decreased risk of celiac disease in patients with helicobacter pylori colonization". Am J Epidemiol 2014;179(10):1275
27. Ivarsson A, Persson LA, Nystrom L, et al. Epidemic of coeliac disease in Swedish children. Acta Paediatr 2000;89(2):165-71
28. Marild K, Stephansson O, Montgomery S, et al. Pregnancy outcome and risk of celiac disease in offspring: a nationwide case-control study. Gastroenterology 2012;142(1):39-45.e3
29. Lebwohl B, Blaser MJ, Ludvigsson JF, et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol 2013;178(12):1721-30
30. Henriksson C, Bostrom AM, Wiklund IE. What effect does breastfeeding have on coeliac disease? A systematic review update. Evid Based Med 2013;18(3):98-103
31. Logan RF. Malignancy in unrecognised coeliac disease: a nail in the coffin for mass screening? Gut 2009;58(5):618-19
32. Card TR, West J, Holmes GK. Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study. Aliment Pharmacol Ther 2004;20(7):769-75
33. West J, Logan RF, Smith CJ, et al. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004;329(7468):716-19
34. Olen O, Askling J, Ludvigsson JF, et al. Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtype. Dig Liver Dis 2011;43(11):862-8
35. Gough KR, Read AE, Naish JM. Intestinal reticulosis as a complication of idiopathic steatorrhoea. Gut 1962;3:232-9
36. Harris OD, Cooke WT, Thompson H, Waterhouse JA. Malignancy in adult coeliac disease and idiopathic steatorrhoea. Am J Med 1967;42(6):899-912
37. Holmes GK, Stokes PL, Sorahan TM, et al. Coeliac disease, gluten-free diet, and malignancy. Gut 1976;17(8):612-19
38. Cooper BT, Holmes GK, Cooke WT. Lymphoma risk in coeliac disease of later life. Digestion 1982;23(2):89-92
39. Kane EV, Newton R, Roman E. Non-Hodgkin lymphoma and gluten-sensitive enteropathy: estimate of risk using meta-analyses. Cancer Causes Control 2011;22(10):1435-44
40. Meyer D, Stavropolous S, Diamond B, et al. Osteoporosis in a North American adult population with celiac disease. Am J Gastroenterol 2001;96(1):112-19
41. Olmos M, Antelo M, Vazquez H, et al. Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Dig Liver Dis 2008;40(1):46-53
42. Passananti V, Santonicola A, Bucci C, et al. Bone mass in women with celiac disease: role of exercise and gluten-free diet. Dig Liver Dis 2012;44(5):379-83
43. Ciclitira P, Dewar DH, McLaughlin SD, Sanders DS. The management of adults with coeliac disease. Br Soc Gastroenterol 2010. Accessed online www.bsg.org.uk/images/stories/clinical/bsg-coeliac-10.pdf
44. Hall NJ, Rubin G, Charnock A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009;30(4):315-30
45. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42(3):200-9
46. Rubio-Tapia A, Hill ID, Kelly CP, American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108(5):656-76; quiz 77
47. Biagi F, Campanella J, Martucci S, et al. A milligram of gluten a day keeps the mucosal recovery away: a case report. Nutr Rev 2004;62(9):360-3
48. Akobeng AK, Thomas AG. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 2008;27(11):1044-52
49. Sharkey LM, Corbett G, Currie E, et al. Optimising delivery of care in coeliac disease-comparison of the benefits of repeat biopsy and serological follow-up. Aliment Pharmacol Ther 2013;38(10):1278-91
50. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med 2013;159(3):169-75
51. Lebwohl B, Michaelsson K, Green PH, Ludvigsson JF. Persistent mucosal damage and risk of fracture in celiac disease. J Clin Endocrinol Metab 2014;99(2):609-16
52. Barratt SM, Leeds JS, Sanders DS. Quality of life in Coeliac Disease is determined by perceived degree of difficulty adhering to a gluten-free diet, not the level of dietary adherence ultimately achieved. J Gastrointestin Liver Dis 2011;20(3):241-5
53. Barratt SM, Leeds JS, Robinson K, et al. Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011;23(2):159-65
54. Aziz I, Evans KE, Papageorgiou V, Sanders DS. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J Gastrointestin Liver Dis 2011;20(1):27-31
55. Elli L. Coeliac disease: between "pizza" and ethics. Gut 2006;55(11):1672
56. West J, Fleming KM, Tata LJ, et al. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study. Am J Gastroenterol 2014;109(5):757-68
57. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther 2007;26(9):1217-25
58. Dydensborg S, Toftedal P, Biaggi M, et al. Increasing prevalence of coeliac disease in Denmark: a linkage study combining national registries. Acta Paediatr 2012;101(2):179-84
59. White LE, Merrick VM, Bannerman E, et al. The rising incidence of celiac disease in Scotland. Pediatrics 2013;132(4):e924-31
60. Wang XQ, Liu W, Xu CD, et al. Celiac disease in children with diarrhea in 4 cities in China. J Pediatr Gastroenterol Nutr 2011;53(4):368-70
61. Kochhar R, Sachdev S, Kochhar R, et al. Prevalence of coeliac disease in healthy blood donors: a study from north India. Dig Liver Dis 2012;44(6):530-2
62. Green PH, Neugut AI, Naiyer AJ, et al. Economic benefits of increased diagnosis of celiac disease in a national managed care population in the United States. J Insur Med 2008;40(3-4):218-28
63. Long KH, Rubio-Tapia A, Wagie AE, et al. The economics of coeliac disease: a population-based study. Aliment Pharmacol Ther 2010;32(2):261-9
64. Violato M, Gray A, Papanicolas I, Ouellet M. Resource use and costs associated with coeliac disease before and after diagnosis in 3, 646 cases: results of a UK primary care database analysis. PLoS One 2012;7(7):e41308
65. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and mortality in coeliac disease. Aliment Pharmacol Ther 2013;37(3):332-9
66. Sollid LM, Qiao SW, Anderson RP, et al. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 2012;64(6):455-60
67. Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002;297(5590):2275-9
68. Hausch F, Shan L, Santiago NA, et al. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002;283(4):G996-g1003
69. Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137(6):1912-33
70. Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 2005;129(3):797-806
71. Gianfrani C, Siciliano RA, Facchiano AM, et al. Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology 2007;133(3):780-9
72. Di Cagno R, De Angelis M, Auricchio S, et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 2004;70(2):1088-96
73. Pyle GG, Paaso B, Anderson BE, et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol 2005;3(7):687-94
74. Lahdeaho ML, Kaukinen K, Laurila K, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014;146(7):1649-58
75. Mitea C, Havenaar R, Drijfhout JW, et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008;57(1):25-32
76. Gass J, Bethune MT, Siegel M, et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007;133(2):472-80
77. Tack GJ, van de Water JM, Bruins MJ, et al. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J Gastroenterol 2013;19(35):5837-47
78. Gass J, Ehren J, Strohmeier G, et al. Fermentation, purification, formulation, and pharmacological evaluation of a prolyl endopeptidase from Myxococcus xanthus: implications for Celiac Sprue therapy. Biotechnol Bioeng 2005;92(6):674-84
79. Shan L, Marti T, Sollid LM, et al. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 2004;383(Pt 2):311-18
80. Siegel M, Bethune MT, Gass J, et al. Rational design of combination enzyme therapy for celiac sprue. Chem Biol 2006;13(6):649-58
81. Siegel M, Garber ME, Spencer AG, et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci 2012;57(2):440-50
82. Tye-Din JA, Anderson RP, Ffrench RA, et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol 2010;134(3):289-95
83. Stepniak D, Spaenij-Dekking L, Mitea C, et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006;291(4):G621-9
84. Lindfors K, Blomqvist T, Juuti-Uusitalo K, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152(3):552-8
85. Lu R, Wang W, Uzzau S, et al. Affinity purification and partial characterization of the zonulin/zonula occludens toxin (Zot) receptor from human brain. J Neurochem 2000;74(1):320-6
86. Uzzau S, Lu R, Wang W, et al. Purification and preliminary characterization of the zonula occludens toxin receptor from human (CaCo2) and murine (IEC6) intestinal cell lines. FEMS Microbiol Lett 2001;194(1):1-5
87. Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007;26(5):757-66
88. Dhal PK, Polomoscanik SC, Avila LZ, et al. Functional polymers as therapeutic agents: concept to market place. Adv Drug Deliv Rev 2009;61(13):1121-30
89. Pinier M, Verdu EF, Nasser-Eddine M, et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009;136(1):288-98
90. Matysiak-Budnik T, Malamut G, de Serre NP, et al. Long-term follow-up of 61 coeliac patients diagnosed in childhood: evolution toward latency is possible on a normal diet. Gut 2007;56(10):1379-86
91. Patriarca G, Pogna N, Cammarota G, et al. An attempt of specific desensitising treatment with gliadin in celiac disease. Int J Immunopathol Pharmacol 2005;18(4):709-14
92. Senger S, Luongo D, Maurano F, et al. Intranasal administration of a recombinant alpha-gliadin down-regulates the immune response to wheat gliadin in DQ8 transgenic mice. Immunol Lett 2003;88(2): 127-34
93. Keech CL, Dromey J, Chen Z, et al. 355 immune tolerance induced by peptide immunotherapy in an HLA Dq2-dependent mouse model of gluten immunity. Gastroenterology 2009;136(5):A-57
94. Brown GJ, Daveson J, Marjason JK, et al. A phase I study to determine safety, tolerability and bioactivity of Nexvax2® in HLA DQ2+ volunteers with celiac disease following a long-term, strict gluten-free diet. Gastroenterology 2011;140(5):S-437-S-38
95. Quinnell RJ, Bethony J, Pritchard DI. The immunoepidemiology of human hookworm infection. Parasite Immunol 2004;26(11-12):443-54
96. Daveson AJ, Jones DM, Gaze S, et al. Effect of hookworm infection on wheat challenge in celiac disease-a randomised double-blinded placebo controlled trial. PLoS One 2011;6(3):e17366
97. Rauhavirta T, Oittinen M, Kivisto R, et al. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol 2013;33(1):134-42
98. Xia J, Siegel M, Bergseng E, et al. Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin. J Am Chem Soc 2006;128(6):1859-67
99. Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003;52(2):218-23
100. Drago S, El Asmar R, Di Pierro M, et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41(4):408-19
101. Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 2000;113(Pt 24):4435-40
102. Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 2012;107(10):1554-62
103. Kelly CP, Green PH, Murray JA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 2013;37(2):252-62
104. Wang C, Rasmussen H, Perrow W, et al. 929b larazotide acetate, a first in-class, novel tight junction regulator, meets primary endpoint and significantly reduces signs and symptoms of celiac disease in patients on a gluten-free diet: results of a multicenter, randomized, placebo controlled trial. Gastroenterology 2014;146(5):S-159
105. Smecuol E, Bai JC, Vazquez H, et al. Gastrointestinal permeability in celiac disease. Gastroenterology 1997;112(4):1129-36
106. Kaukinen K, Sulkanen S, Maki M, Collin P. IgA-class transglutaminase antibodies in evaluating the efficacy of gluten-free diet in coeliac disease. Eur J Gastroenterol Hepatol 2002;14(3):311-15
107. Tye-Din JA, Stewart JA, Dromey JA, et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010;2(41):41ra51
108. Heyman M, Abed J, Lebreton C, Cerf-Bensussan N. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut 2012;61(9):1355-64